The GISS Trial: a Phase II Prevention Trial of Screening Plus Goserelin, Ibandronate, versus Screening Alone in Premenopausal Women at Increased Risk of Breast CancerVON MINCKWITZ, Gunter; LOIBL, Sibylle; VESCIA, Sabine et al.Cancer epidemiology, biomarkers & prevention. 2011, Vol 20, Num 10, pp 2141-2149, issn 1055-9965, 9 p.Article

Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: Results of a randomised trial (GABG-IV E-93) - The German Adjuvant Breast Cancer GroupEIERMANN, Wolfgang; GRAF, Erika; KAUFMANN, Manfred et al.European journal of cancer (1990). 2010, Vol 46, Num 1, pp 84-94, issn 0959-8049, 11 p.Article

A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer : GABG-IV B-93KAUFMANN, Manfred; GRAF, Erika; VON MINCKWITZ, Gunter et al.European journal of cancer (1990). 2007, Vol 43, Num 16, pp 2351-2358, issn 0959-8049, 8 p.Article

CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients : A randomised trial (GABG trial IV-A-93)VON MINCKWITZ, Gunter; GRAF, Erika; KAUFMANN, Manfred et al.European journal of cancer (1990). 2006, Vol 42, Num 12, pp 1780-1788, issn 0959-8049, 9 p.Article